Compare First Citizens BancShares Inc (FCNCA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Incyte Corporation — how do they compare? First Citizens BancShares Inc trades at $2,278.08 (market cap $25.04B), while Incyte Corporation trades at $120.72 (market cap $24.54B). The key difference: First Citizens BancShares Inc and Incyte Corporation are close in size by market cap, and First Citizens BancShares Inc pays a 0.37% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| FCNCA | INCY | |
|---|---|---|
Market Cap | $25.04B | $24.54B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $129.93 |
52-Week Low | $1.64K | $81.61 |
Dividend Yield | 0.37% | — |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,276, up 1.91% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by recent earnings beats. Recent news highlights business expansion, including new financing groups and real estate acquisitions.
Outlook is positive with analyst consensus price target of $2,310, though most analysts rate it Hold. Key risks include elevated uninsured deposits and net interest margin pressure. Earnings growth and strategic initiatives provide upside potential, but investor caution is warranted near current levels.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
